U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Guidance, Compliance & Regulatory Information (Biologics)
  4. Biologics Post-Market Activities
  5. Lot Release
  6. Influenza Vaccine for the 2022-2023 Season
  1. Lot Release

Influenza Vaccine for the 2022-2023 Season

FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on March 3, 2022, to select the influenza viruses for the composition of the influenza vaccine for the 2022-2023 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2021-2022 vaccines, and the availability of candidate strains and reagents.

Influenza virus strains were selected based on the influenza vaccine production method; egg-based and cell- or recombinant-based.

The committee recommended that the quadrivalent formulation of egg-based influenza vaccines for the U.S. 2022-2023 influenza season contain the following:

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
  • an A/Darwin/9/2021 (H3N2)-like virus;
  • a B/Austria/1359417/2021-like virus (B/Victoria lineage); and
  • a B/Phuket/3073/2013-like virus (B/Yamagata lineage).

The committee recommended that the quadrivalent formulation of cell- or recombinant-based influenza vaccines for the U.S. 2022-2023 influenza season contain the following:

  • an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
  • an A/Darwin/6/2021 (H3N2)-like virus;
  • a B/Austria/1359417/2021-like virus (B/Victoria lineage); and
  • a B/Phuket/3073/2013-like virus (B/Yamagata lineage).

For trivalent influenza vaccines for use in the U.S. for the 2022-2023 influenza season, depending on the manufacturing method of the vaccine, the committee recommended that the A(H1N1)pdm09, A(H3N2) and B/Austria/1359417/2021-like virus (B/Victoria lineage) viruses recommended above for the quadrivalent vaccines be used.

 

Back to Top